How much money can drug companies make in 2019? This one may be the big winner

[pharmaceutical network industry trends] recently, the financial performance of pharmaceutical listed companies in the third quarter of 2019 has been disclosed From the data point of view, the profit growth rate of the pharmaceutical industry in the first three quarters was 10%, and the overall trend was downward, which was related to the impact of policies such as volume procurement implemented in 2019 However, in the third quarter, the growth rate of the profit end of the pharmaceutical industry increased slightly on a month-on-month basis, with overall steady growth and obvious sub industry differentiation Now, near the end of the year, how much money pharmaceutical companies can earn in 2019 has become a topic in the industry A number of companies said that as the industry tends to be stable, they have confidence in the performance development in the fourth quarter of this year It is reported that the net profit of Huahai pharmaceutical industry in the fourth quarter may reach about 180 million, and the net profit in 2019 will reach 720 million, a year-on-year increase of 434% According to the disclosed financial data, Huahai pharmaceutical achieved an operating revenue of 4.012 billion from January to September 2019, an increase of 4.39% year on year In terms of net profit level, the company's net profit in the first three quarters was 545 million, up 95% year on year, and the net profit in the third quarter was 191 million It is expected that in the fourth quarter, the net profit will be about 180 million, which is basically the same as or slightly lower than that in the third quarter In 2019, the net profit will be 720 million, an increase of 434% year on year It is estimated that the level of net profit in 2020 will be about 900 million, with a year-on-year increase of 28% According to the data, Huahai pharmaceutical may become a big winner this year As far as the external favorable factors are concerned, with the trend of aging and chronic diseases spreading in China, although the price reduction of generic drugs has become a major trend with the promotion of policies such as volume purchase and medical insurance cost control, the domestic demand is also increasing, and the game of competing speed and cost of generic drugs industry has begun, while Huahai pharmaceutical industry is undoubtedly in the grasp of operational research In the first round of centralized purchase catalog, many varieties only compete with Huahai pharmaceutical industry and original research and development company Huahai pharmaceutical industry has become one of the most successful enterprises in volume purchase The winning varieties include irbesartan oral, paroxetine oral, risperidone oral, irbesartan hydrochlorothiazide oral, lisinopril oral, losartan oral and other drugs On September 1, Shanghai Sunshine pharmaceutical purchasing network released the centralized purchasing document of drugs in the alliance area, which made it clear that the centralized purchasing of 25 varieties (specifications) of drugs purchased in batches will be expanded to 25 alliance provinces and cities, and will be promoted nationwide. In the pilot expansion, consistency evaluation will be used as the quality threshold of generic drugs At that time, in the list of drugs that had passed the consistency evaluation, Huahai pharmaceutical had passed 20 drugs, and 6 products were overrated   According to the rules, winning the "over evaluation" means getting the "admission ticket" to participate in the centralized procurement The seven varieties of "irbesartan tablets, irbesartan hydrochlorothiazide tablets, losartan potassium tablets, fosinoprina tablets, lisinopril tablets, paroxetine hydrochloride tablets, and risperidone tablets" participated in the centralized procurement bidding by Huahai pharmaceutical Co., Ltd won the bidding, which will bring revenue and profit to the company Quantity In addition, Huahai pharmaceutical has 63 anda approvals from the United States, and the company also hopes to report 15-20 varieties annually in the future The industry believes that this part of the varieties may bring a large increase According to the industry, under the policy of drug volume purchase, the competition among pharmaceutical enterprises is largely cost competition, including production cost, purchase cost, employment cost, etc However, some segments suffered less impact, including pharmaceutical companies with less product competition, such as palosidine and Sinopharm, a competitor of lisinopril.